Clinical, Diagnostic and Therapeutic Framework of mHSPC and nmCRPC: A Multidisciplinary Consensus Project of the Italian Society for Uro-Oncology (SIUrO)

This publication has 67 references indexed in Scilit:

• Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022
  European Journal of Cancer, 2023
• nmCRPC, a look in the continuous care of prostate cancer patients: state of art and future perspectives
  Cancer Treatment Reviews, 2023
• Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours
  Cancer Treatment Reviews, 2022
• What do we need to obtain high quality circulating tumor DNA (ctDNA) for routine diagnostic test in oncology? – Considerations on pre-analytical aspects by the IFCC workgroup cfDNA
  Clinica Chimica Acta, 2021
• The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM–SIAPEC-IAP–SIBioC–SIC–SIF Italian Scientific Societies
  ESMO Open, 2021
• Cross-resistance and drug sequence in prostate cancer
  Drug Resistance Updates, 2021
• Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer
  JAMA Oncology, 2021
• The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide
  Cancer Treatment Reviews, 2017
• Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High‐Age Patients (CRASH) score
  Cancer, 2011
• A comparative study of differences in subjective likelihood estimates made by individuals, interacting groups, Delphi groups, and nominal groups
  Organizational Behavior and Human Performance, 1973